CONy16: New Alzheimer’s Phase 3 Tests of Amyloid-Beta Immunotherapies and an Exclusive Interview with Researcher

CONy16: New Alzheimer’s Phase 3 Tests of Amyloid-Beta Immunotherapies and an Exclusive Interview with Researcher
Two previously failed drug candidates, Eli Lilly’s Solanezumab and Roche’s Gantenerumab, are again under clinical study for Alzheimer’s disease. Both drugs are immunotherapies targeting amyloid-beta in the brain, a target that researchers — including Dr. Michael Geschwind, who spoke with Alzheimer's News Today — think has the potential to revolutionize Alzheimer’s treatment. Amyloid-beta has long been the focus of Alzheimer’s research, especially over the past decade. Many of the potential treatments used an immunotherapeutic slant to stop the protein's toxicity, and hence prevent or slow disease progression. Solanezumab and Gantenerumab, both monoclonal antibodies against amyloid-beta, looked promising in animal studies. Yet, while clinical trials showed the drugs to be safe, results repeatedly failed to produce convincing evidence that they might alter disease progression. Both pharmaceutical companies have now re-launched efforts in new Phase 3 clinical trials. Eli Lilly announced last year that Solanezumab successfully demonstrated an impact on disease progression in its early stages in the ongoing EXPEDITION 3 trial. A group of patients who received the drug after a waiting period had a decline that closely paralleled but remained behind those in a group receiving treatment from the start. Patients treated later never caught up with patients treated earlier in cognitive and functional assessments, a
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *